PTC Therapeutics (NASDAQ:PTCT – Get Free Report) is projected to announce its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $0.22 per share and revenue of $298.6320 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.42. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The business had revenue of $272.55 million for the quarter, compared to analyst estimates of $217.42 million. During the same period in the prior year, the company earned $10.04 EPS. PTC Therapeutics’s revenue for the quarter was up 43.5% on a year-over-year basis. On average, analysts expect PTC Therapeutics to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.
PTC Therapeutics Price Performance
Shares of NASDAQ:PTCT traded down $2.08 during midday trading on Tuesday, reaching $73.72. The company’s stock had a trading volume of 324,250 shares, compared to its average volume of 1,453,732. The company has a market capitalization of $6.12 billion, a P/E ratio of -31.67, a P/E/G ratio of 6.69 and a beta of 0.53. PTC Therapeutics has a fifty-two week low of $43.17 and a fifty-two week high of $90.87. The business’s fifty day simple moving average is $77.30 and its 200-day simple moving average is $72.82.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on PTC Therapeutics
Insider Activity
In other news, insider Eric Pauwels sold 21,277 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $75.00, for a total value of $1,595,775.00. Following the completion of the sale, the insider directly owned 73,411 shares of the company’s stock, valued at $5,505,825. This represents a 22.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew B. Klein sold 12,572 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $72.95, for a total transaction of $917,127.40. Following the transaction, the chief executive officer directly owned 393,998 shares in the company, valued at $28,742,154.10. The trade was a 3.09% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 198,662 shares of company stock valued at $16,347,994. Insiders own 5.50% of the company’s stock.
Institutional Investors Weigh In On PTC Therapeutics
Institutional investors have recently bought and sold shares of the company. LPL Financial LLC acquired a new stake in shares of PTC Therapeutics in the 4th quarter valued at approximately $225,000. Van ECK Associates Corp acquired a new position in PTC Therapeutics during the fourth quarter worth $217,000. VARCOV Co. bought a new stake in PTC Therapeutics during the fourth quarter worth $207,000. CIBC Private Wealth Group LLC acquired a new stake in PTC Therapeutics in the fourth quarter valued at $191,000. Finally, Picton Mahoney Asset Management acquired a new stake in PTC Therapeutics in the fourth quarter valued at $173,000.
About PTC Therapeutics
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Featured Articles
- Five stocks we like better than PTC Therapeutics
- Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
- 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?
- Whirlpool’s Report May Show How Frozen the Housing Market Really Is
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
